Sign in

    Thomas E. Polen

    Chairman, CEO, and President at Becton Dickinson and Co
    Since January 2020
    Age
    51 years
    Tenure
    Joined BD over twenty years ago and advanced through various leadership roles including Executive Vice President and President - Medical Segment from October 2014 to April 2017, President since April 2017, Chief Operating Officer from October 2018 to January 2020, CEO since January 2020, and Chairman since April 2021.

    Also at Becton Dickinson and Co

    CJD
    Christopher J. DelOrefice
    Executive Vice President and Chief Financial Officer
    DS
    David Shan
    Executive Vice President and Chief Integrated Supply Chain Officer
    MF
    Michael Feld
    Executive Vice President and President, Life Sciences Segment

    About

    Thomas E. Polen is 51 years old and has spent over two decades at Becton, Dickinson and Company, demonstrating his long-term commitment to the organization. Over the years, he has progressively taken on higher levels of responsibility, starting with his role as Executive Vice President and President - Medical Segment from October 2014 to April 2017, then transitioning to the role of President in April 2017.

    Building on his success, he served as Chief Operating Officer between October 2018 and January 2020 before assuming the role of Chief Executive Officer in January 2020. His journey continued as he took on the additional responsibility of Chairman in April 2021, reflecting his leadership in steering the company's strategic initiatives and operational excellence.

    Under his guidance, BD has focused on innovation, strategic acquisitions, and sustainability, including transformative projects that have positioned the firm as a global MedTech leader. His career at BD highlights a trajectory of continuous professional growth and a deep understanding of the medical technology industry, making him a central figure in BD’s ongoing transformation and success.

    $BDX Performance Under Thomas E. Polen

    Past Roles

    OrganizationRoleDate RangeDetails
    BD (Becton, Dickinson and Company) Chief Operating Officer October 2018 - January 2020 N/A
    BD (Becton, Dickinson and Company) President April 2017 - N/A N/A
    BD (Becton, Dickinson and Company) Executive Vice President and President - Medical Segment October 2014 - April 2017 N/A

    External Roles

    OrganizationRoleDate Range
    Walgreens Boots Alliance Director N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Salary$1,354,813 AnnualFixed annual base salary.
    All Other Compensation$269,760 AnnualIncludes Matching and discretionary contributions: $45,225 and Corporate aircraft and travel expenses: $224,535 .

    Performance Compensation

    Data from  FY 2024

    Performance Incentive Plan (PIP) and Associated Equity Awards

    ComponentDetails / Metrics
    Performance Units (PUs)Grant Date: November 26, 2023 <br>Metrics: Average Annual Revenue Growth and Average Annual ROIC (weighted 50% each) <br>Modifier: Adjusted by relative TSR compared to peers <br>Payout Range: 0% to 200% <br>Vesting Schedule: Cliff vest in 3 years (2024-2026) <br>Grant Date Fair Value: $6,600,225 (target), $13,200,450 (maximum)
    PIP Dollar TargetsThreshold: $1,023,563 <br>Target: $2,047,125 <br>Maximum: $4,094,250
    Time-Vested Units (TVUs)Grant Date: November 26, 2023 <br>Units: 11,429 <br>Grant Date Fair Value: $2,644,328 <br>Vesting Schedule: Graded vesting over 3 years
    Stock Appreciation Rights (SARs)Grant Date: November 26, 2023 <br>Units: 63,335 <br>Exercise Price: $238.89 <br>Grant Date Fair Value: $3,993,272 <br>Vesting Schedule: 4 equal annual installments starting 1 year after grant <br>Note: Value based solely on stock price appreciation.

    Evaluation Period and Additional Details

    • Evaluation Period: 3 years (2024-2026) for Performance Units.
    • Performance Conditions: Payout is determined by actual performance against set metrics with scaling applied from 0% to 200% of target payout.
    • No reported actual performance outcomes for 2024 are available in the provided data.

    This detailed breakdown covers the performance compensation components and metrics applicable for 2024 using the available information.